Current Report Filing (8-k)
August 02 2022 - 06:00AM
Edgar (US Regulatory)
0001808805FALSEDelaware001-3943498-15417232701 Eastlake Avenue
EastSeattleWashington9810200018088052022-08-022022-08-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 2,
2022
NAUTILUS BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
001-39434
(Commission File Number)
|
|
98-1541723
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
2701 Eastlake Avenue East
Seattle, Washington
(Address of principal executive offices)
|
|
98102
(Zip code)
|
(206) 333-2001
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
|
|
|
|
|
o |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
o |
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
o |
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
NAUT
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. o
Item 2.02. Results of Operations and
Financial Condition.
On August 2, 2022, Nautilus Biotechnology, Inc. issued a press
release reporting its financial results for the quarter ended
June 30, 2022. A copy of the press release is furnished
herewith as Exhibit 99.1 to this Current Report on Form
8-K.
The information furnished in this Current Report under Item 2.02
and the exhibit attached hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
|
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
Description |
|
|
|
104 |
|
Cover page Interactive Data File (embedded with the Inline XBRL
document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
Dated: August 2, 2022
|
|
|
|
|
|
|
|
|
|
NAUTILUS BIOTECHNOLOGY, INC. |
|
|
|
|
By: |
/s/ Sujal Patel |
|
Name: |
Sujal Patel |
|
Title: |
Chief Executive Officer |
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Apr 2023 to May 2023
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From May 2022 to May 2023